OMER
Omeros Corporation
$14.13
-3.48%
2026-05-08
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Key Fundamentals
Forward P/E
11.35
EPS (TTM)
$-0.08
Profit Margin
0.0%
Beta
2.66
Market Cap
$1.05B
Avg Volume (10D)
1.1M
Recent Breakout Signals
No recent breakout signals detected for OMER.
Recent Price Range (60 Days)
60D High
$15.32
60D Low
$9.77
Avg Volume
1.0M
Latest Close
$14.13
Get breakout alerts for OMER
Sign up for Breakout Scanner to receive daily notifications when OMER triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Omeros Corporation (OMER) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors OMER daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. OMER operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.